{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T03:32:50Z","timestamp":1768707170572,"version":"3.49.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2010,4,9]],"date-time":"2010-04-09T00:00:00Z","timestamp":1270771200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2011,2]]},"DOI":"10.1007\/s00280-010-1315-z","type":"journal-article","created":{"date-parts":[[2010,4,8]],"date-time":"2010-04-08T11:24:10Z","timestamp":1270725850000},"page":"275-284","source":"Crossref","is-referenced-by-count":18,"title":["Schedule treatment design and quantitative in vitro evaluation of chemotherapeutic combinations for metastatic prostate cancer therapy"],"prefix":"10.1007","volume":"67","author":[{"given":"Ana Catarina","family":"Pinto","sequence":"first","affiliation":[]},{"given":"Susana","family":"\u00c2ngelo","sequence":"additional","affiliation":[]},{"given":"Jo\u00e3o Nuno","family":"Moreira","sequence":"additional","affiliation":[]},{"given":"S\u00e9rgio","family":"Sim\u00f5es","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2010,4,9]]},"reference":[{"key":"1315_CR1","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1634\/theoncologist.7-4-360","volume":"7","author":"S Goodin","year":"2002","unstructured":"Goodin S, Rao KV, DiPaola RS (2002) State-of-the-art treatment of metastatic hormone-refractory prostate cancer. Oncologist 7:360\u2013370","journal-title":"Oncologist"},{"key":"1315_CR2","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ctrv.2005.12.005","volume":"32","author":"G Sonpavde","year":"2006","unstructured":"Sonpavde G, Hutson TE, Berry WR (2006) Hormone refractory prostate cancer: management and advances. Cancer Treat Rev 32:90\u2013100","journal-title":"Cancer Treat Rev"},{"key":"1315_CR3","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1177\/030089160308900402","volume":"89","author":"G Di Lorenzo","year":"2003","unstructured":"Di Lorenzo G, Autorino R, De Laurentiis M, Bianco R, Lauria R, Giordano A, De Sio M, D\u2019Armiento M, Bianco AR, De Placido S (2003) Is there a standard chemotherapeutic regimen for hormone-refractory prostate cancer? Present and future approaches in the management of the disease. Tumori 89:349\u2013360","journal-title":"Tumori"},{"key":"1315_CR4","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0090-4295(99)00064-3","volume":"54","author":"AM Kamat","year":"1999","unstructured":"Kamat AM, DeHaven JI, Lamm DL (1999) Quinolone antibiotics: a potential adjunct to intravesical chemotherapy for bladder cancer. Urology 54:56\u201361","journal-title":"Urology"},{"key":"1315_CR5","first-page":"207","volume":"21","author":"BF El-Rayes","year":"2002","unstructured":"El-Rayes BF, Grignon R, Aslam N, Aranha O, Sarkar FH (2002) Ciprofloxacin inhibits cell growth and synergises the effect of etoposide in hormone resistant prostate cancer cells. Int J Oncol 21:207\u2013211","journal-title":"Int J Oncol"},{"key":"1315_CR6","first-page":"787","volume":"22","author":"O Aranha","year":"2003","unstructured":"Aranha O, Grignon R, Fernandes N, McDonnell TJ, Wood DP Jr, Sarkar FH (2003) Suppression of human prostate cancer cell growth by ciprofloxacin is associated with cell cycle arrest and apoptosis. Int J Oncol 22:787\u2013794","journal-title":"Int J Oncol"},{"key":"1315_CR7","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1097\/00001813-200002000-00009","volume":"11","author":"A Hubert","year":"2000","unstructured":"Hubert A, Lyass O, Pode D, Gabizon A (2000) Doxil (Caelyx): an exploratory study with pharmacokinetics in patients with hormone-refractory prostate cancer. Anticancer Drugs 11:123\u2013127","journal-title":"Anticancer Drugs"},{"key":"1315_CR8","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.uct.2008.02.001","volume":"3","author":"KR Hande","year":"2008","unstructured":"Hande KR (2008) Topoisomerase II inhibitors. Update Cancer Ther 3:13\u201326","journal-title":"Update Cancer Ther"},{"key":"1315_CR9","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1016\/S0959-8049(98)00228-7","volume":"34","author":"KR Hande","year":"1998","unstructured":"Hande KR (1998) Etoposide: four decades of development of a topoisomerase II inhibitor. Eur J Cancer 34:1514\u20131521","journal-title":"Eur J Cancer"},{"key":"1315_CR10","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1517\/14656566.1.2.271","volume":"1","author":"JM Kamradt","year":"2000","unstructured":"Kamradt JM, Pienta KJ (2000) Etoposide in prostate cancer. Expert Opin Pharmacother 1:271\u2013275","journal-title":"Expert Opin Pharmacother"},{"key":"1315_CR11","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1038\/sj.bjc.6603941","volume":"97","author":"G Vlahovic","year":"2007","unstructured":"Vlahovic G, Ponce AM, Rabbani Z, Salahuddin FK, Zgonjanin L, Spasojevic I, Vujaskovic Z, Dewhirst MW (2007) Treatment with imatinib improves drug delivery and efficacy in NSCLC xenografts. Br J Cancer 97:735\u2013740","journal-title":"Br J Cancer"},{"key":"1315_CR12","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/pros.20130","volume":"62","author":"K Rao","year":"2005","unstructured":"Rao K, Goodin S, Levitt MJ, Dave N, Shih WJ, Lin Y, Capanna T, Doyle-Lindrud S, Juvidian P, DiPaola RS (2005) A phase II trial of imatinib mesylate in patients with prostate specific antigen progression after local therapy for prostate cancer. Prostate 62:115\u2013122","journal-title":"Prostate"},{"key":"1315_CR13","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0167-4781(98)00134-1","volume":"1400","author":"KR Hande","year":"1998","unstructured":"Hande KR (1998) Clinical applications of anticancer drugs targeted to topoisomerase II. Biochim Biophys Acta 1400:173\u2013184","journal-title":"Biochim Biophys Acta"},{"key":"1315_CR14","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1200\/JCO.1996.14.6.1756","volume":"14","author":"IF Tannock","year":"1996","unstructured":"Tannock IF, Osoba D, Stockler MR, Ernst DS, Neville AJ, Moore MJ, Armitage GR, Wilson JJ, Venner PM, Coppin CM, Murphy KC (1996) Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 14:1756\u20131764","journal-title":"J Clin Oncol"},{"issue":"Suppl 4","key":"1315_CR15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00003495-199200444-00002","volume":"44","author":"XJ Zhou","year":"1992","unstructured":"Zhou XJ, Rahmani R (1992) Preclinical and clinical pharmacology of vinca alkaloids. Drugs 44(Suppl 4):1\u201316 (discussion 66\u201319)","journal-title":"Drugs"},{"key":"1315_CR16","unstructured":"Hardman JG, Limbird LE, Gilman AG (2001) Goodman LSPbot: Goodman & Gilman\u2019s the pharmacological basis of therapeutics. In: Hardman JG, Limbird LE (eds)\/Alfred Goodman Gilman (consulting ed) 10th edn. McGraw-Hill, New York, London"},{"key":"1315_CR17","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s00280-008-0892-6","volume":"64","author":"AC Pinto","year":"2009","unstructured":"Pinto AC, Moreira JN, Simoes S (2009) Ciprofloxacin sensitizes hormone-refractory prostate cancer cell lines to doxorubicin and docetaxel treatment on a schedule-dependent manner. Cancer Chemother Pharmacol 64:445\u2013454","journal-title":"Cancer Chemother Pharmacol"},{"key":"1315_CR18","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/0165-6147(83)90490-X","volume":"4","author":"TC Chou","year":"1983","unstructured":"Chou TC, Talalay P (1983) Analysis of combined drug effects: a new look at a very old problem. Trends Pharmacol Sci 4:450\u2013454","journal-title":"Trends Pharmacol Sci"},{"key":"1315_CR19","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","volume":"22","author":"TC Chou","year":"1984","unstructured":"Chou TC, Talalay P (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22:27\u201355","journal-title":"Adv Enzyme Regul"},{"key":"1315_CR20","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1159\/000423478","volume":"19","author":"TC Chou","year":"1994","unstructured":"Chou TC (1994) Assessment of synergistic and antagonistic effects of chemotherapeutic agents in vitro. Contrib Gynecol Obstet 19:91\u2013107","journal-title":"Contrib Gynecol Obstet"},{"key":"1315_CR21","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1097\/00001813-200211000-00005","volume":"13","author":"DR Budman","year":"2002","unstructured":"Budman DR, Calabro A, Kreis W (2002) Synergistic and antagonistic combinations of drugs in human prostate cancer cell lines in vitro. Anticancer Drugs 13:1011\u20131016","journal-title":"Anticancer Drugs"},{"key":"1315_CR22","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/BF00685668","volume":"31","author":"TC Chou","year":"1993","unstructured":"Chou TC, Tan QH, Sirotnak FM (1993) Quantitation of the synergistic interaction of edatrexate and cisplatin in vitro. Cancer Chemother Pharmacol 31:259\u2013264","journal-title":"Cancer Chemother Pharmacol"},{"key":"1315_CR23","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1007\/s002800000191","volume":"47","author":"W Kreis","year":"2001","unstructured":"Kreis W, Budman DR, Calabro A (2001) A reexamination of PSC 833 (Valspodar) as a cytotoxic agent and in combination with anticancer agents. Cancer Chemother Pharmacol 47:78\u201382","journal-title":"Cancer Chemother Pharmacol"},{"key":"1315_CR24","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/BF00685096","volume":"31","author":"GL Wampler","year":"1992","unstructured":"Wampler GL, Carter WH Jr, Campbell ED, Keefe PA (1992) Relationships between various uses of antineoplastic drug-interaction terms. Cancer Chemother Pharmacol 31:111\u2013117","journal-title":"Cancer Chemother Pharmacol"},{"key":"1315_CR25","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S0165-6147(97)90658-1","volume":"18","author":"G Capranico","year":"1997","unstructured":"Capranico G, Binaschi M, Borgnetto ME, Zunino F, Palumbo M (1997) A protein-mediated mechanism for the DNA sequence-specific action of topoisomerase II poisons. Trends Pharmacol Sci 18:323\u2013329","journal-title":"Trends Pharmacol Sci"},{"key":"1315_CR26","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1021\/bi962488f","volume":"36","author":"SH Elsea","year":"1997","unstructured":"Elsea SH, Westergaard M, Burden DA, Lomenick JP, Osheroff N (1997) Quinolones share a common interaction domain on topoisomerase II with other DNA cleavage-enhancing antineoplastic drugs. Biochemistry 36:2919\u20132924","journal-title":"Biochemistry"},{"key":"1315_CR27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/20014091074165","volume":"36","author":"RP Bakshi","year":"2001","unstructured":"Bakshi RP, Galande S, Muniyappa K (2001) Functional and regulatory characteristics of eukaryotic type II DNA topoisomerase. Crit Rev Biochem Mol Biol 36:1\u201337","journal-title":"Crit Rev Biochem Mol Biol"},{"key":"1315_CR28","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.canlet.2006.11.005","volume":"252","author":"A Montecucco","year":"2007","unstructured":"Montecucco A, Biamonti G (2007) Cellular response to etoposide treatment. Cancer Lett 252:9\u201318","journal-title":"Cancer Lett"},{"key":"1315_CR29","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/S0959-8049(98)00435-3","volume":"35","author":"JP Brussel van","year":"1999","unstructured":"van Brussel JP, van Steenbrugge GJ, Romijn JC, Schroder FH, Mickisch GH (1999) Chemosensitivity of prostate cancer cell lines and expression of multidrug resistance-related proteins. Eur J Cancer 35:664\u2013671","journal-title":"Eur J Cancer"},{"key":"1315_CR30","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1128\/AAC.33.10.1697","volume":"33","author":"JF Barrett","year":"1989","unstructured":"Barrett JF, Gootz TD, McGuirk PR, Farrell CA, Sokolowski SA (1989) Use of in vitro topoisomerase II assays for studying quinolone antibacterial agents. Antimicrob Agents Chemother 33:1697\u20131703","journal-title":"Antimicrob Agents Chemother"},{"key":"1315_CR31","doi-asserted-by":"crossref","first-page":"35927","DOI":"10.1074\/jbc.274.50.35927","volume":"274","author":"VE Anderson","year":"1999","unstructured":"Anderson VE, Zaniewski RP, Kaczmarek FS, Gootz TD, Osheroff N (1999) Quinolones inhibit DNA religation mediated by Staphylococcus aureus topoisomerase IV. Changes in drug mechanism across evolutionary boundaries. J Biol Chem 274:35927\u201335932","journal-title":"J Biol Chem"},{"key":"1315_CR32","doi-asserted-by":"crossref","first-page":"7406","DOI":"10.1074\/jbc.M212056200","volume":"278","author":"KD Bromberg","year":"2003","unstructured":"Bromberg KD, Burgin AB, Osheroff N (2003) A two-drug model for etoposide action against human topoisomerase IIalpha. J Biol Chem 278:7406\u20137412","journal-title":"J Biol Chem"},{"key":"1315_CR33","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s00280-003-0579-y","volume":"51","author":"WM Liu","year":"2003","unstructured":"Liu WM, Joel SP (2003) The schedule-dependent effects of etoposide in leukaemic cell lines: a function of concentration and duration. Cancer Chemother Pharmacol 51:291\u2013296","journal-title":"Cancer Chemother Pharmacol"},{"key":"1315_CR34","doi-asserted-by":"crossref","first-page":"3393","DOI":"10.1021\/bi027383t","volume":"42","author":"KD Bromberg","year":"2003","unstructured":"Bromberg KD, Burgin AB, Osheroff N (2003) Quinolone action against human topoisomerase IIalpha: stimulation of enzyme-mediated double-stranded DNA cleavage. Biochemistry 42:3393\u20133398","journal-title":"Biochemistry"},{"key":"1315_CR35","doi-asserted-by":"crossref","first-page":"25231","DOI":"10.1074\/jbc.275.33.25231","volume":"275","author":"MP Boland","year":"2000","unstructured":"Boland MP, Fitzgerald KA, O\u2019Neill LA (2000) Topoisomerase II is required for mitoxantrone to signal nuclear factor kappa B activation in HL60 cells. J Biol Chem 275:25231\u201325238","journal-title":"J Biol Chem"},{"key":"1315_CR36","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1021\/bi0019141","volume":"40","author":"D Leroy","year":"2001","unstructured":"Leroy D, Kajava AV, Frei C, Gasser SM (2001) Analysis of etoposide binding to subdomains of human DNA topoisomerase II alpha in the absence of DNA. Biochemistry 40:1624\u20131634","journal-title":"Biochemistry"},{"issue":"Suppl 5","key":"1315_CR37","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/S0959-8049(02)80600-1","volume":"38","author":"E Buchdunger","year":"2002","unstructured":"Buchdunger E, O\u2019Reilly T, Wood J (2002) Pharmacology of imatinib (STI571). Eur J Cancer 38(Suppl 5):28\u201336","journal-title":"Eur J Cancer"},{"key":"1315_CR38","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1002\/pros.20201","volume":"63","author":"HR Kubler","year":"2005","unstructured":"Kubler HR, van Randenborgh H, Treiber U, Wutzler S, Battistel C, Lehmer A, Wagenpfeil S, Hartung R, Paul R (2005) In vitro cytotoxic effects of imatinib in combination with anticancer drugs in human prostate cancer cell lines. Prostate 63:385\u2013394","journal-title":"Prostate"},{"key":"1315_CR39","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S0065-230X(06)97011-0","volume":"97","author":"A Ostman","year":"2007","unstructured":"Ostman A, Heldin CH (2007) PDGF receptors as targets in tumor treatment. Adv Cancer Res 97:247\u2013274","journal-title":"Adv Cancer Res"},{"key":"1315_CR40","doi-asserted-by":"crossref","first-page":"879","DOI":"10.2165\/00003088-200544090-00001","volume":"44","author":"B Peng","year":"2005","unstructured":"Peng B, Lloyd P, Schran H (2005) Clinical pharmacokinetics of imatinib. Clin Pharmacokinet 44:879\u2013894","journal-title":"Clin Pharmacokinet"},{"key":"1315_CR41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.eururo.2003.08.011","volume":"45","author":"HG Poel van der","year":"2004","unstructured":"van der Poel HG (2004) Smart drugs in prostate cancer. Eur Urol 45:1\u201317","journal-title":"Eur Urol"},{"key":"1315_CR42","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S0006-2952(98)00307-4","volume":"57","author":"DA Gewirtz","year":"1999","unstructured":"Gewirtz DA (1999) A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol 57:727\u2013741","journal-title":"Biochem Pharmacol"},{"key":"1315_CR43","first-page":"379","volume":"44","author":"KR Hande","year":"1984","unstructured":"Hande KR, Wedlund PJ, Noone RM, Wilkinson GR, Greco FA, Wolff SN (1984) Pharmacokinetics of high-dose etoposide (VP-16\u2013213) administered to cancer patients. Cancer Res 44:379\u2013382","journal-title":"Cancer Res"},{"key":"1315_CR44","doi-asserted-by":"crossref","first-page":"365","DOI":"10.2165\/00003088-199018050-00003","volume":"18","author":"G Ehninger","year":"1990","unstructured":"Ehninger G, Schuler U, Proksch B, Zeller KP, Blanz J (1990) Pharmacokinetics and metabolism of mitoxantrone. A review. Clin Pharmacokinet 18:365\u2013380","journal-title":"Clin Pharmacokinet"},{"key":"1315_CR45","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1177\/0091270003262101","volume":"44","author":"B Peng","year":"2004","unstructured":"Peng B, Dutreix C, Mehring G, Hayes MJ, Ben-Am M, Seiberling M, Pokorny R, Capdeville R, Lloyd P (2004) Absolute bioavailability of imatinib (Glivec) orally versus intravenous infusion. J Clin Pharmacol 44:158\u2013162","journal-title":"J Clin Pharmacol"},{"key":"1315_CR46","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","volume":"344","author":"BJ Druker","year":"2001","unstructured":"Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S, Sawyers CL (2001) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344:1031\u20131037","journal-title":"N Engl J Med"},{"key":"1315_CR47","doi-asserted-by":"crossref","first-page":"57S","DOI":"10.1016\/0002-9343(89)90023-5","volume":"87","author":"KG Naber","year":"1989","unstructured":"Naber KG, Sorgel F, Kees F, Jaehde U, Schumacher H (1989) Pharmacokinetics of ciprofloxacin in young (healthy volunteers) and elderly patients, and concentrations in prostatic fluid, seminal fluid, and prostatic adenoma tissue following intravenous administration. Am J Med 87:57S\u201359S","journal-title":"Am J Med"},{"key":"1315_CR48","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1128\/AAC.26.5.741","volume":"26","author":"MA Gonzalez","year":"1984","unstructured":"Gonzalez MA, Uribe F, Moisen SD, Fuster AP, Selen A, Welling PG, Painter B (1984) Multiple-dose pharmacokinetics and safety of ciprofloxacin in normal volunteers. Antimicrob Agents Chemother 26:741\u2013744","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-010-1315-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-010-1315-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-010-1315-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,3]],"date-time":"2020-06-03T16:02:02Z","timestamp":1591200122000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-010-1315-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,4,9]]},"references-count":48,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,2]]}},"alternative-id":["1315"],"URL":"https:\/\/doi.org\/10.1007\/s00280-010-1315-z","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,4,9]]}}}